chumma Posted December 18, 2004 Share Posted December 18, 2004 Iressa failed to show survival advantage in a large clinical trial. You may read the FDA notification regarding this issue at http://medicineworld.org/news/lungNews.html Tarceva, taxotere and alimta are still options in this setting Regards Betsy Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.